Kuros Biosciences (XSWX:KURN) COGS-to-Revenue : 0.36 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences COGS-to-Revenue?

Kuros Biosciences's Cost of Goods Sold for the six months ended in Dec. 2023 was CHF7.49 Mil. Its Revenue for the six months ended in Dec. 2023 was CHF20.70 Mil.

Kuros Biosciences's COGS to Revenue for the six months ended in Dec. 2023 was 0.36.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Kuros Biosciences's Gross Margin % for the six months ended in Dec. 2023 was 63.83%.

Kuros Biosciences COGS-to-Revenue Historical Data

The historical data trend for Kuros Biosciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences COGS-to-Revenue Chart

Kuros Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.87

0.59

0.27

0.40

0.29

Kuros Biosciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.39	0.18	0.71	0.17	0.36

Kuros Biosciences COGS-to-Revenue Calculation

Kuros Biosciences's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	9.628	/	33.564
	=	0.29

Kuros Biosciences's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	7.486	/	20.698
	=	0.36

Kuros Biosciences (XSWX:KURN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Kuros Biosciences's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	7.486 / 20.698
	=	63.83 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Kuros Biosciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Kuros Biosciences (XSWX:KURN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

CSBTF:USA KURNz:UK

Address

Wagistrasse 25, Schlieren, Zurich, CHE, 8952

Website

https://www.kurosbio.com

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences (XSWX:KURN) Headlines

No Headlines